Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC
CompanyDrug

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC

Astellas Pharma Inc. (TYO: 4503) announced that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, an investigational targeted protein degrader, versus docetaxel in patients with…

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

BMS’s Yervoy-Opdivo Combo on Track for Breakthrough Therapy Designation in China for CRC

CompanyDrug

Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE

CompanyDrug

J&J’s Rybrevant Secures Full FDA Approval for NSCLC with EGFR Exon 20 Insertions

CompanyDeals

Haihe Pharmaceuticals Licenses Glumetinib to Taiho for Exclusive Development in Japan and Asia

CompanyDrug

Fosun Pharmaceutical Secures NMPA Approval for Phase II Study of FCN-338 and FCN-647 in Chronic Lymphocytic Leukemia

CompanyDrug

Jiangsu Hengrui Receives NMPA Approval for HRS-1167 Clinical Trials in Advanced Solid Tumors

CompanyDrug

CDE Grants Priority Review to Jiu An’s Adrenaline and AnHeart’s Taletrectinib; Two Others Earn Breakthrough Therapy Designation

CompanyDrug

CARsgen Therapeutics’ BCMA-targeted CAR-T Cell Therapy Approved by China’s NMPA

Show More